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Adopting an integrative approach, by combining studies of cardiovascular func-
tion with those at cellular and molecular levels, this study investigated whether 
maternal treatment with melatonin protects against programmed cardiovascular 
dysfunction in the offspring using an established rodent model of hypoxic preg-
nancy. Wistar rats were divided into normoxic (N) or hypoxic (H, 10% O2) preg-
nancy  ±  melatonin (M) treatment (5  μg·ml−1.day−1) in the maternal drinking 
water. Hypoxia ± melatonin treatment was from day 15– 20 of gestation (term is 
ca. 22 days). To control for possible effects of maternal hypoxia- induced reduc-
tions in maternal food intake, additional dams underwent pregnancy under nor-
moxic conditions but were pair- fed (PF) to the daily amount consumed by hypoxic 
dams from day 15 of gestation. In one cohort of animals from each experimental 
group (N, NM, H, HM, PF, PFM), measurements were made at the end of gesta-
tion. In another, following delivery of the offspring, investigations were made at 
adulthood. In both fetal and adult offspring, fixed aorta and hearts were studied 
stereologically and frozen hearts were processed for molecular studies. In adult 
offspring, mesenteric vessels were isolated and vascular reactivity determined by 
in- vitro wire myography. Melatonin treatment during normoxic, hypoxic or pair- 
fed pregnancy elevated circulating plasma melatonin in the pregnant dam and 
fetus. Relative to normoxic pregnancy, hypoxic pregnancy increased fetal haema-
tocrit, promoted asymmetric fetal growth restriction and resulted in accelerated 
postnatal catch- up growth. Whilst fetal offspring of hypoxic pregnancy showed 
aortic wall thickening, adult offspring of hypoxic pregnancy showed dilated car-
diomyopathy. Similarly, whilst cardiac protein expression of eNOS was down-
regulated in the fetal heart, eNOS protein expression was elevated in the heart 
of adult offspring of hypoxic pregnancy. Adult offspring of hypoxic pregnancy 
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1 |  INTRODUCTION
It has been estimated that about one- third of all non- 
communicable chronic diseases in humans is linked to 
prenatal determinants of adult health and pathology.1 
Cardiovascular disease, one of the greatest killers in the 
world today, is no exception. It is well documented that 
a component of cardiovascular dysfunction in adult off-
spring can be programmed by adverse intrauterine con-
ditions.2 One of the most common suboptimal pregnancy 
conditions is chronic fetal hypoxia,3 and it is well estab-
lished that hypoxic pregnancy can increase cardiovascular 
risk in the adult progeny.4,5
The hypothesis that oxidative stress and reductions in 
nitric oxide (NO) signalling during fetal cardiovascular 
development provides a molecular link between chronic 
fetal hypoxia and an increased susceptibility of the adult 
offspring to cardiovascular dysfunction has gained im-
portant ground in recent years.4,6- 9 This line of thinking 
gave rise to interventional studies in hypoxic pregnancy 
reporting that maternal treatment with antioxidants, such 
as vitamin C, could prevent oxidative stress in the fetal 
heart and vasculature, enhance NO signalling and thereby 
protect the adult offspring from programmed cardiovascu-
lar dysfunction.6,10,11 However, in such studies, only high 
doses of vitamin C proved effective.6,10,11 This is problem-
atic because excess vitamin C can increase the formation 
of renal calculi12 and maternal treatment with high doses 
of vitamin C during human pregnancy can increase the 
rate of babies born with a low birthweight.13 Therefore, 
there is interest in identifying alternative maternal ther-
apy with improved human translational potential. Recent 
studies have focussed either on increasing oxygen deliv-
ery, to avoid oxidative stress in the first instance,14,15 or 
using alternative antioxidant therapy.16- 18
Melatonin may be a prime candidate to protect against 
oxidative stress and impaired NO signalling during devel-
opment, given that it is a small and amphipathic indol-
amine that displays low toxicity and high efficacy at low 
and safe doses.19 Melatonin shows multi- level, intra- and 
extra- cellular mechanisms of action, including powerful 
direct and indirect antioxidant properties20- 22 and NO- 
dependent cardioprotective effects.23- 25 Melatonin crosses 
the placenta26 and protects placental perfusion and fetal 
growth in preclinical animal models of adverse pregnan-
cy.27- 29 Consequently, ongoing clinical trials are testing the 
efficacy of melatonin in protecting fetal growth in human 
high- risk pregnancy.30 Maternal melatonin treatment also 
mitigates coronary stiffness in growth- restricted newborn 
lambs.31 However, whether beneficial effects of melatonin 
transcend to protect the adult offspring from cardiovas-
cular dysfunction in hypoxic pregnancy has not been 
investigated.
Therefore, this study tested the hypothesis that mater-
nal treatment with low doses of melatonin during hypoxic 
pregnancy will protect the progeny against cardiovascular 
remodelling and dysfunction. The hypothesis was tested 
using an established model of hypoxic pregnancy in rats, 
combining functional outcomes with cellular and molec-
ular experiments in a longitudinal design at two stages of 
life: in the fetus at the end of gestation and in the adult 
offspring at 4  months of age. Maternal exposure to hy-
poxia can decrease maternal food intake.32- 35 Therefore, 
our experimental design included a subset of additional 
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pregnancies to control for possible hypoxia- induced re-
ductions in maternal food intake.
2 |  MATERIALS AND METHODS
2.1 | Animals, breeding and housing
The study was approved by the Cambridge University 
Animal Welfare and Ethical Review Board. All proce-
dures were carried out under the UK Animals (Scientific 
Procedures) 1986 Act. Wistar rats (Charles River Limited) 
were brought into the University of Cambridge Central 
Biomedical Services and housed in individually ventilated 
cages (IVC units, 21% O2, 70– 80 air changes per hour) in 
rooms with controlled humidity (60%), controlled tem-
perature (21°C) and a 12:12 hour light- dark cycle (lights 
on at 0700 h) with free access to food (maintenance diet, 
Charles River, UK) and water. After 10 days of acclimati-
zation, virgin female Wistar rats between 10 and 12 weeks 
of age were paired individually with male Wistar rats, 
aged minimum 12 weeks in an individual cage. Paper be-
neath a gridded insert placed at the bottom of the cage was 
checked daily for the presence of a copulatory plug to indi-
cate mating. The presence of a copulatory plug was taken 
to be day 0 of pregnancy (term ~22 days). Upon finding a 
plug, the female was weighed and housed individually in a 
fresh cage with free access to 200 g VRF1 diet (Special Diet 
Services) and water. Maternal weight, and food and water 
consumption were monitored daily.
2.2 | Induction of hypoxia
On day 15 of gestation, pregnant females were randomly 
assigned to one of four experimental groups: Normoxic 
(N), Normoxic  +  Melatonin (NM), Hypoxic (H) and 
Hypoxic + Melatonin (HM); with n = 7 per group reserved 
for studies at the end of gestation, and n  = 8 per group 
reserved for studies in the adult offspring at 4 months of 
age. Pregnant rats assigned to hypoxia were placed inside 
a transparent hypoxic chamber that could house nine rat 
cages in a tranquil environment, as previously described 
in detail.35,36 The chronic hypoxia chamber combined a 
PVC isolator (PFI Plastics Ltd.) with a nitrogen genera-
tor (N2MID60, Dominick Hunter Ltd). The percentage of 
oxygen in the chamber could be controlled with precision 
over long periods, without changes in ambient carbon di-
oxide, by altering the inflow and outflow of air and nitro-
gen in the chamber. The chamber had the same number 
of air changes as the normoxic individual ventilated cages 
and was housed in the same room. The chamber con-
tained a battery- operated hygrometer and thermometer 
for continuous monitoring of humidity and temperature 
whilst the oxygen concentration of the chamber was mon-
itored throughout with an oxygen analyzer (ICA).
Pregnancies undergoing maternal hypoxia were main-
tained at an inspired fraction of oxygen of 10% from day 
15 of gestation. In experiments in sheep pregnancy, in 
which the fetus can be catheterized long- term, we have 
shown that this level of maternal hypoxia results in fetal 
arterial PO2 values between 11 and 13 mmHg.
37- 40 This is 
the PO2 measured by cordocentesis in human fetuses in 
pregnancy affected by chronic fetal hypoxia and intrauter-
ine growth restriction.41 Therefore, this model of hypoxic 
pregnancy is of human clinical relevance.
Maternal exposure to 10% O2 isobaric hypoxia can de-
crease maternal food intake.34,35 Therefore, an additional 
n = 30 dams underwent pregnancy under normoxic condi-
tions but were pair- fed (PF) to the daily amount consumed 
by hypoxic dams from day 15 of gestation. Half of them 
received melatonin treatment (PFM) and n = 7 per group 
were reserved for studies at the end of gestation, and n = 8 
per group were reserved for studies in the adult offspring 
at 4 months of age.
2.3 | Maternal treatment 
with melatonin
Normoxic, hypoxic and pair- fed pregnancies were ran-
domly assigned for treatment with melatonin in the ma-
ternal drinking water. Melatonin was initially dissolved in 
the minimum volume of ethanol (three drops) and then 
made up with water to achieve a final concentration of 
5 μg·ml−1. The final concentration of ethanol in the solu-
tion was <0.01%. The solutions were prepared fresh every 
other day and were administered using opaque bottles to 
prevent light- induced degradation. The dose of melatonin 
was equivalent to the maximal dose recommended for 
overcoming jet lag in humans.42 Dams not receiving mela-
tonin in their drinking water were given a vehicle contain-
ing three drops of ethanol per 500 ml drinking water.
2.4 | Studies at the end of gestation
On the morning of day 20 of gestation, the dams were 
weighed. Anaesthesia was induced with inhalational iso-
flurane and then maintained by a mixture of ketamine 
(40 mg·kg−1) and xylazine (5 mg·kg−1) injected intraperi-
toneally.35 Once anaesthetized, a maternal blood sample 
(5  ml) was taken by cardiac puncture. The mother was 
killed under anaesthesia and the pregnant uterus exposed 
via a mid- line incision. The anaesthetized pups were then 
isolated and killed via cervical spinal transection. In dams 
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that had been in the hypoxic chamber from days 15– 20 
of gestation, this procedure was carried out whilst venti-
lated with 10% oxygen via a face mask. Fetal blood was 
collected from the neck incision by capillarity into haema-
tocrit tubes and pooled per litter. Maternal and fetal blood 
was either centrifuged in a Hawksley centrifuge for deter-
mination of haematocrit or centrifuged at 300 g for 5 min, 
aliquoted and frozen for subsequent analysis of plasma 
concentrations of melatonin. All fetuses and their associ-
ated placentae were isolated and weighed. The fetal sex 
was noted by measurement of the anogenital distance.35,36 
Four male and four female fetuses from each litter under-
went detailed biometry including measurement of crown- 
rump length (CRL). The heart, liver, and brain of one male 
fetus per litter were dissected and weighed. The placenta 
and heart from one male fetus per litter were snap- frozen 
in liquid nitrogen and stored at −80°C for subsequent pro-
tein expression analysis. The thorax of another male fetus 
per litter was immersion fixed in 4% paraformaldehyde for 
5 days, and then stored in phosphate- buffered saline until 
it was processed into paraffin blocks for histological analy-
sis of the heart and the aorta.
2.5 | Studies in the adult offspring at 
4 months of age
At birth, all neonates were sexed and weighed, and each 
litter was reduced to eight pups (four males and four fe-
males) to standardize nutritional intake. The male pups 
were marked and weighed three times a week until 
weaning at 21  days of age. At weaning, the mother and 
female weanlings were culled, and tissues were collected 
for other studies. The remaining male offspring were 
group- housed, weighed twice a week, and maintained 
until 16 weeks of age. At 16 weeks of age, male offspring 
were randomly assigned to organ dissection or the inves-
tigation of peripheral vascular reactivity by in vitro wire 
myography. Those males used for organ dissection were 
weighed and then anaesthetized with inhalational isoflu-
rane and a mixture of ketamine (40 mg·kg−1) and xylazine 
(5  mg·kg−1) injected intraperitoneally. Then, they were 
killed by exsanguination under general anaesthesia. The 
heart and descending aorta were dissected. The heart was 
weighed, then the left ventricle + interventricular septum 
and right ventricular wall were dissected and weighed. 
The left ventricle was divided into two halves. The bot-
tom half was snap- frozen in liquid nitrogen and stored at 
−80°C for subsequent protein expression analysis. The top 
half of the left ventricle and a section of the descending 
aorta at the level of the apex of the heart were immersion 
fixed separately in 4% paraformaldehyde for 5  days and 
then stored in phosphate- buffered saline until they were 
processed into paraffin blocks for subsequent histological 
analysis.
2.6 | Melatonin assay
Maternal and pooled fetal blood samples were collected 
in chilled heparinized or ethylenediaminetetraacetic 
acid (EDTA) tubes and centrifuged at 300 g for 5  min. 
Plasma aliquots were snap- frozen in liquid nitrogen and 
maintained frozen at −80°C until analysis. The concen-
tration of melatonin in both maternal and fetal plasma 
was determined in all samples at the same time, as be-
fore.27 Briefly, melatonin levels were determined using 
the 2- [125I]iodomelatonin Rat RIA Kit (MP Biomedicals, 
Eschwege, Germany; code 07L- 130102). The sensitivity of 
the assay was 1.5 pg/ml and the inter- and intra- assay co-
efficients of variation were <12%. The melatonin antise-
rum showed <1% cross- reactivity with N- acetylserotonin, 
5- methoxytryptophol and 5- methoxytryptamine and 
<0.01% with other related amines.
2.7 | Stereology
All quantitative analysis of fixed tissue obtained from 
the fetal pups and from the adult offspring was carried 
out with an Olympus BX- 50  microscope with objective 
lenses (×1.25 and ×10 and oil immersion ×100), a motor-
ized specimen stage and microcator using the Computer 
Assisted Stereology Toolbox (CAST version2.0, Olympus). 
Paraffin- embedded fetal thoraces and the left ventricles 
and aorta isolated from the adult offspring were exhaus-
tively sectioned at 5 μm using a Leica RM 2235 microtome 
(Leica Microsystems). To determine wall and lumen 
areas, 10 sections were selected at an equal distance apart 
at the level of the cardiac valves for the fetal and adult 
hearts, and at a level of the apex of the heart for the de-
scending aorta of the adult offspring. Prepared slides were 
then stained with Masson's Trichrome. A point grid was 
superimposed on each section and areas were quantified 
as before43- 45 using the Cavalieri's principle.46 Points fall-
ing on either the wall or lumen were counted, and areas 
were calculated as A(obj) = a(p) x ΣP, where A(obj) is the 
estimated area, a(p) is the area associated with each point 
and ΣP is the sum of points falling on the relevant area, av-
eraged over the sections. To account for shrinkage due to 
immersion fixing and paraffin processing, the diameter of 
erythrocytes present in sections of fetal or adult fixed tis-
sue was measured and compared to the diameter of eryth-
rocytes present in fresh blood from foetal or adult rats of 
the same age.47 All measurements were corrected using 
this factor.
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2.8 | Western blot analysis
Tissue homogenization to obtain protein lysates and sub-
sequent sodium dodecyl sulphate– polyacrylamide gel 
electrophoresis and immunoblotting were performed, 
as previously.27,48 The specific primary antibodies were 
rabbit polyclonal to 4- Hydroxynonenal (4- HNE; 1:2000; 
Abcam, code 210767) and heat shock protein 70 (HSP70; 
1:20 000; Stressgen, code Spa812C); mouse monoclonal to 
heat shock proteins 27 (HSP27; 1:1500; Cell Signaling, code 
2442), endothelial NOS (eNOS; 1:2500; BD Transduction 
Labs, code 610297) and β- actin (1:50  000; Sigma, code 
A5441). The horseradish peroxidase- conjugated secondary 
antibodies were from GE Healthcare UK Ltd (anti- rabbit 
and - mouse). Membranes were re- probed with antibody 
recognizing β- actin to control for protein loading and to 
normalize relative levels of protein expression. The optical 
density of the immunoreactive bands was analysed using 
ImageJ software (National Institutes of Health; http://rsb.
info.nih.gov/ij), and the ratio protein to β- actin was calcu-
lated for each sample.
2.9 | Ex vivo wire myography
Adult offspring assigned to ex- vivo wire myography were 
killed via carbon dioxide inhalation and kept on ice until 
dissection of the vessels. Immediately after euthanasia, 
the small intestine was removed, placed in ice- cold Krebs 
buffer (mmol·l−1: NaCl 118.5, Fisher, KCl 4.75, Sigma, 
MgSO4·7H20 1.2, Sigma, KH2PO4 1.2, Sigma, NaHCO3 
25.0, Sigma, CaCl2 2.5, Sigma, glucose 5.5, Sigma) and 
a second order branch of the mesenteric artery was dis-
sected. A 2 mm arterial segment was cut and mounted in 
a four- chamber small- vessel wire myograph (Multi Wire 
Myograph System 610  M, DMT, Denmark). One jaw of 
the myograph was connected to a micrometre screw and 
the other to a force transducer, which was connected to a 
data acquisition system (Powerlab 8/30, ADInstruments), 
as before.36,49,50 A digital camera (Olympus) connected to 
one of the eye- pieces of the microscope displayed a live 
image of the vessel on a computer screen. The length and 
diameter of the unstretched vessel segment could then 
be measured from the digital image and corrected using 
a known scale factor. The myograph baths were main-
tained at 37°C and continuously aerated with a gas mix-
ture of 95% O2 and 5% CO2. After a stabilization period 
of 15– 20 min, the vessels were stretched to an equivalent 
physiological transmural pressure of 100  mmHg.36,49,50 
The internal circumference (IC) corresponding to this 
transmural pressure was calculated using the equation: 
IC = π*D*2(D + d), where D was the diameter (40 μm) of 
and d was the distance between the wires. After 30 min 
of incubation under resting tension, a control reference 
contraction was elicited by raising the K+ concentration 
of the buffer (125  mmol/L) in exchange for Na+. After 
washing the vessels three times with Krebs buffer and 
waiting for 20  min, cumulative concentration- response 
curves to the α1- adrenergic agonist phenylephrine (PE; 
10−9– 10−4 mol/L) and the thromboxane mimetic U46619 
(10−10– 10−6  mol/L) were determined in half- log incre-
ments. Arteries were given 15– 20  min resting and equi-
libration period between experiments. The responses to 
phenylephrine and to U46619 were normalized to the 
response to 125  mM K+ of the same vessel (%K+125). 
LabChart was used for data acquisition and analysis 
(LabChart 6.0, Powerlab 8/30; AD Instruments).
2.10 | Data and statistical analyses
Previous data sets with a similar experimental design were 
used to determine appropriate power calculations to de-
termine minimum sample sizes required to achieve statis-
tical significance.27,35,36,48- 50 Wherever possible, scientists 
measuring outcomes were blinded to treatments. For in-
stance, to minimize bias, all histological analysis was per-
formed using coded slides, with the observer blinded to 
the treatment groups.
Postnatal fractional growth rate (FGR) was calculated 
as the change in bodyweight over the period of interest, 
divided by the number of days within that period. For 
the wire myography analysis, sensitivity (expressed as 
pD2 = - log EC50) and maximal response (Kmax) to agonists 
(PE and U46619) were determined by fitting individual 
concentration- response data to a non- linear sigmoidal 
regression curve using Prism 6.0 (GraphPad software), as 
before.36,50,51 For the molecular biology and histological 
studies, values given as percentages or ratios were first 
transformed to arcsin to equalize variance.52
All data are expressed as the mean ± SEM. Comparisons 
between experimental groups were made using Two- way 
ANOVA, with repeated measures, as appropriate. If the 
ANOVA showed a significant interaction between factors, 
statistical differences between groups were isolated using 
the Tukey post hoc test (SigmaStat for Windows, Version 
2.0; SPSS Inc.). To account for the sex of the offspring and 
within litter variation, data from one male pup per litter 
for any one outcome variable were taken. Exceptions were 
data describing biometry for the fetal study at the end of 
gestation, such as fetal and placental weights, CRL and 
BMI. For these outcomes, where more than one values 
originated from anyone litter, a Mixed Linear Model anal-
ysis was used to consider within litter variation (SPSS for 
Windows, Version 16; SPSS Inc.). For all statistical com-
parisons, p < 0.05 was considered statistically significant.
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3 |  RESULTS
3.1 | Maternal food intake, maternal 
water consumption and maternal weight 
gain
In all pregnancies irrespective of treatment, maternal 
food and water intake between days 0 and 15 of gestation 
did not vary significantly and averaged 23.1 ± 0.3 g and 
46.3 ± 0.8 ml per day, respectively. In normoxic pregnan-
cies, maternal food intake was significantly increased rel-
ative to baseline from day 16. In contrast, hypoxic dams 
ate significantly less than control pregnancies from days 
16– 21 of gestation (Figure  1A,B). This equated to a ca. 
35% reduction in maternal food consumption relative to 
normoxic pregnancies (p  <  0.05). Relative to normoxic 
dams, maternal water consumption also fell transiently in 
hypoxic pregnancies, on days 16 and 17 of gestation, but 
returned to control values for the remainder of gestation 
(Figure 1A,B). All dams gained weight through pregnancy 
and were significantly heavier than their weight at con-
ception from day 10 of gestation onwards. Relative to nor-
moxic dams, hypoxic pregnancies put on significantly less 
weight during days 16– 21 of gestation (Figure 1A,B). The 
daily profile of maternal food intake in hypoxic dams was 
successfully replicated in dams undergoing pair- feeding 
(Figure 1A,B). Maternal treatment with melatonin did not 
affect maternal food or water consumption, or changes 
in maternal weight gain in normoxic, hypoxic or pair- fed 
pregnancies (Figure 1A,B).
To maintain clarity, presentation of the data in graphic 
form from now on will focus on comparison between nor-
moxic and hypoxic pregnancies with and without mater-
nal treatment with melatonin. Presentation of the data 
pertaining to additional pair- fed control groups will ap-
pear in text or in a table.
3.2 | Melatonin concentrations and 
haematocrit
Plasma concentrations of melatonin measured at day 
20 of gestation were higher in the pregnant dam than 
in the corresponding fetuses (p  <  0.05). Hypoxia did 
not alter maternal or fetal plasma melatonin concen-
trations (Figure 2A,B). Similarly, pair- feeding did not 
alter maternal (N, 20.1 ± 4.9 vs. PF, 33.7 ± 8.5 pg/ml; 
p > .05) or fetal (N, 6.2 ± 1.9 vs. PF, 8.4 ± 4.7 pg/ml; 
p > 0.05) plasma melatonin concentrations. Relative to 
untreated pregnancies, maternal treatment with mela-
tonin significantly increased the plasma concentration 
of melatonin in normoxic and hypoxic mothers and 
fetuses at day 20 of gestation (p < 0.05; Figure 2A,B). 
Similarly, relative to untreated pregnancies, maternal 
treatment with melatonin significantly increased the 
plasma concentration of melatonin in pair- fed mothers 
(255.2 ± 72.2 pg/ml) and fetuses (134.3 ± 36.7 pg/ml) 
at day 20 of gestation (both p < 0.05). Hypoxia signifi-
cantly increased maternal and fetal haematocrit at day 
20 of gestation (Figure 2A,B). Maternal treatment with 
melatonin had no effect on maternal or fetal haemato-
crit in normoxic or hypoxic pregnancies (Figure 2A,B).
3.3 | Pregnancy characteristics
Litter size at birth was similar across all groups (N: 
13.6 ± 1.0, NM: 13.1 ± 0.4, H: 12.7 ± 1.0, HM: 12.5 ± 0.7, 
PF: 12.6 ± 1.3, PFM: 12.7 ± 1.1). Relative to fetuses of nor-
moxic pregnancy, fetal bodyweight, crown- rump length 
(CRL) and body mass index (BMI) at day 20 of gestation 
were similarly reduced in hypoxic pregnancy with or 
without melatonin (p < 0.001; Figure 3A– C). Relative to 
fetuses of normoxic pregnancy, the fetal brain:liver weight 
ratio was similarly increased in hypoxic pregnancy with or 
without melatonin (p < 0.001; Figure 3D). Relative to nor-
moxic pregnancy, hypoxic pregnancy did not affect pla-
cental weight, but melatonin treatment similarly reduced 
placental weight in normoxic and hypoxic pregnancy 
(p  <  0.05; Figure  3E). Relative to normoxic pregnancy, 
the fetal body weight:placental weight ratio was similarly 
reduced in hypoxic pregnancy with or without melatonin 
(p < 0.05; Figure 3F). Data derived from the second co-
hort of animals that were allowed to deliver showed that 
relative to pups of normoxic pregnancy, birthweight was 
similarly reduced in hypoxic pregnancy with or without 
melatonin (p  <  0.001; Figure  3G). Conversely, the ges-
tation length was similarly increased in hypoxic preg-
nancy with or without melatonin (p < 0.01; Figure 3H). 
Therefore, relative to pups of normoxic pregnancy, the 
birth weight for gestation length was similarly reduced in 
hypoxic pregnancy with or without melatonin (p < 0.01; 
Figure  3I). Relative to untreated normoxic pregnancy, 
maternal treatment with melatonin in normoxic preg-
nancy did not affect any outcome (Figure 3A– I).
The pregnancy characteristics in pair- fed groups 
with and without melatonin treatment have been 
published as part of another study.27 In brief, fe-
tuses of pair- fed relative to control pregnancies had 
significantly lower fetal bodyweight and fetal body:-
placental weight ratio, higher fetal brain:fetal body-
weight ratio, and lower birth weight [all p <0 .05; 27]. 
Maternal treatment with melatonin in pair- fed preg-
nancy did not affect the reduction in fetal bodyweight 
or the increase in the fetal brain:fetal bodyweight 
ratio. However, maternal treatment with melatonin in 
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pair- fed pregnancy reduced placental weight, which 
restored the fetal body:placental weight ratio and 
birth weight to control values [p < 0.05; 27]. Maternal 
treatment with melatonin in control pregnancies also 
led to significantly lighter placentae (p < 0.05), but it 
had no effect on other variables.27
3.4 | Postnatal growth
Relative to offspring of normoxic pregnancy, offspring of 
hypoxic pregnancy had a significantly greater fractional 
growth rate (FGR) between 0 and 18 weeks of age. Partial 
analysis showed that this effect of hypoxia was in the first 
3 weeks of postnatal life, from birth to weaning (p < 0.01; 
Table 1). Maternal treatment with melatonin in hypoxic 
pregnancy normalized the postnatal FGR and mater-
nal treatment with melatonin in normoxic pregnancy 
had no effect (Table 1). The effect of hypoxic pregnancy 
on postnatal FGR was not independent of an effect of 
hypoxia- induced reductions in maternal food intake be-
cause offspring of pair- fed pregnancies also had a signifi-
cantly increased FGR relative to offspring of normoxic 
pregnancies (p < 0.01; Table 1). Maternal treatment with 
F I G U R E  1  Maternal food intake, maternal water consumption and maternal weight gain. Values are mean ± SEM for the absolute 
values (A) or the change from baseline (B) for maternal food consumption, maternal water consumption and maternal weight gain in 
normoxic (N; white symbols), hypoxic (H; black symbols), hypoxic + melatonin (HM; red symbols), normoxic + melatonin (NM; blue 
symbols), pair- fed (PF; yellow symbols) and pair- fed + melatonin (PFM; green symbols) pregnancies (n = 14 all groups day 0– 20 and n = 7 
for all groups day 20– 22). Significant differences (p < 0.05) are: *, vs. baseline expressed as either day 1– 5 (A) or day 15 (B); †, vs. normoxic 
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melatonin in pair- fed pregnancy also normalized the post-
natal FGR (Table 1).
3.5 | Fetal and adult offspring 
cardiovascular remodelling
The data for the cardiovascular stereology in the fetal 
and adult offspring are summarized in Table  2 and 
Figure  4. Relative to fetuses of normoxic pregnancy, 
fetuses of hypoxic pregnancy had aortic wall thicken-
ing, showing an increase in the aortic wall:lumen area 
(p  <  0.01; Figure  4A) with both a significant increase 
in the wall area and a significant decrease in the lumen 
area, when expressed as a percentage of the total ves-
sel area (p  <  0.01; Figure  4B). These effects of hypoxic 
pregnancy on fetal aortic remodelling were independ-
ent of hypoxic- induced reductions in maternal food in-
take because values for these variables in fetuses from 
pair- fed pregnancies were not different (p>0.05) than 
from normoxic pregnancies (PF fetal aortic wall:llumen 
area = 0.56 ± 0.11; PF fetal aortic lumen area as a % of 
total vessel area = 70.5 ± 8.6; PF fetal aortic wall area as 
a % of total vessel area = 30.8 ± 4.9).
By adulthood, the aortic wall remodelling in offspring 
from hypoxic pregnancy normalized (Table 2). However, 
relative to adult offspring of normoxic pregnancy, these 
adults of hypoxic pregnancy had left ventricles with 
thinner walls, showing a decrease in the wall:lumen area 
ratio (p  <  0.01; Figure  4C), with both a significant de-
crease in the wall area and a significant increase in the 
lumen area, when expressed as a percentage of the total 
left ventricular area (p < 0.01; Figure 4D). As with effects 
in fetal life, these effects of hypoxic pregnancy on car-
diac wall remodelling in the adult were independent of 
hypoxic- induced reductions in maternal food intake be-
cause values for these variables in adult offspring of pair- 
fed pregnancies were not different (p > 0.05) than those 
of normoxic pregnancies (PF adult cardiac wall:llumen 
area = 7.2 ± 1.5; PF adult left ventricular lumen area as a 
% of total heart area = 15.7 ± 1.4; PF left ventricular wall 
area as a % of total heart area = 85.5 ± 5.2).
The effects of hypoxic pregnancy on the wall:lumen 
area ratio of the aorta in the fetus and the left ventricle 
F I G U R E  2  Maternal and fetal melatonin and haematocrit. 
Values are mean ± SEM for maternal (A) and fetal (B) plasma 
concentration of melatonin and haematocrit in normoxic (N; white 
bars), hypoxic (H; black bars), hypoxic + melatonin (HM; red 
bars) and normoxic + melatonin (NM; blue bars) pregnancies at 
gestational day 20. Significant differences (p < 0.05) are: *effect of 
hypoxia; † effect of melatonin (Two- way ANOVA)
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in the adult offspring no longer occurred in hypoxic preg-
nancy treated with melatonin (Figure  4A– D). Maternal 
treatment with melatonin in normoxic pregnancy had 
no effects on the aortic wall:lumen area ratio in fetal life, 
or on the left ventricular wall:lumen area ratio in adult 
life (Figure  4A– D). However, relative to fetuses of nor-
moxic pregnancy, maternal treatment with melatonin in 
normoxic pregnancy led to a significant decrease in the 
left ventricular wall area and thickness (p < 0.05; Table 2). 
Relative to offspring of normoxic pregnancy, offspring 
from pair- fed pregnancies with or without melatonin 
showed a significant decrease in the left ventricular wall 
area in fetal life and a significant decrease in the left ven-
tricular weight in adult life (p < .05; Table 2).
F I G U R E  3  Pregnancy characteristics. Values are mean ± SEM for fetal bodyweight (A), fetal crown- rump length, CRL (B), the fetal 
body mass index, BMI (C), the fetal brain to liver weight ratio (D), the placental weight (E), the fetal to placental weight ratio (F), the birth 
weight (G), the gestational age (H) and the birth weight for gestational age ratio (I) in normoxic (N; white bars), hypoxic (H; black bars), 
hypoxic + melatonin (HM; red bars) and normoxic + melatonin (NM; blue bars) pregnancies. Comparisons of variables relating to fetal 
and placental biometry were assessed using a Generalised Mixed Linear Model (SPSS). This statistical technique permits the experimental 
effects to be assessed on all collected pups and associated placentae considering the size of the litter, thereby negating the need to pool these 


























































































































































































































































































































































































































































































































































































































3.6 | Fetal and adult offspring cardiac 
protein expression
The data for the cardiac protein expression in the fetal and 
adult offspring are summarized in Table 3 and Figure 5. 
Relative to fetuses of normoxic pregnancy, the fetal car-
diac protein expression of eNOS in hypoxic pregnancy was 
significantly reduced (p < 0.05; Figure 5A). This effect of 
hypoxic pregnancy was independent of hypoxic- induced 
reductions in maternal food intake because values for 
cardiac eNOS protein expression in fetuses from pair- fed 
pregnancies were not different relative to those from nor-
moxic pregnancies (0.72 ± 0.34 vs. 1.00 ± 0.27, p > .05). 
Maternal treatment with melatonin in hypoxic pregnancy 
significantly enhanced the fetal cardiac eNOS protein ex-
pression (p < .01) and maternal treatment with melatonin 
in normoxic pregnancy had no effect (Figure 5A).
By contrast, at adulthood, relative to offspring of 
normoxic pregnancy, the cardiac protein expression of 
eNOS in hypoxic pregnancy was significantly increased 
(p  <  0.01; Figure  5B). As with effects in fetal life, this 
effect of hypoxic pregnancy on cardiac eNOS protein 
expression in the adult were independent of hypoxic- 
induced reductions in maternal food intake because 
values for cardiac eNOS protein expression in adult 
offspring of pair- fed pregnancies were significantly re-
duced rather than enhanced in adult offspring from 
pair- fed pregnancies relative to those of normoxic preg-
nancies (0.45 ± 0.03 vs. 1.00 ± 0.08, p < 0.05). Maternal 
treatment with melatonin in normoxic or hypoxic preg-
nancy had no effect on the cardiac protein expression 
of eNOS in adult offspring (Figure 5B). The cardiac pro-
tein expression of HSP27, HSP70 and HNE in hearts of 
fetal or adult offspring was not affected by any treatment 
(Table 3).
3.7 | Vascular function in adult offspring
The outer diameter of the unstretched mesenteric ar-
teries was similar between groups (N: 232  ±  16, NM: 
216 ± 8, H: 207 ± 16, HM: 211 ± 6, PF: 210 ± 24, PFM: 
198 ± 7 μm). In addition, the internal diameter at which 
the arteries reached an intramural pressure of 100 mmHg 
(N: 0.48  ±  0.02, NM: 0.45  ±  0.02, H: 0.48  ±  0.03, HM: 
0.48 ± 0.03, PF: 0.49 + 0.03, PFM: 0.43 + 0.02 mm) and 
the wall tension in response to K+ 125mM (N: 7.61 ± 0.52, 
NM: 7.58  ±  0.75, H: 7.62  ±  0.34, HM 7.53  ±  0.59, PF: 
7.66 ± 0.63, PFM: 7.59 ± 0.33 mN/mm) were similar be-
tween groups.
Relative to adult offspring of normoxic pregnancy, 
mesenteric vessels isolated from adult offspring of hy-
poxic pregnancies showed enhanced sensitivity to PE 
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and U46619, without an effect on maximal contraction 
(p  <  0.01; Figure  6A,B). The effect on vascular sensitiv-
ity of hypoxic pregnancy was independent of effects of 
hypoxia- induced reductions in maternal food intake be-
cause mesenteric vessels isolated from adult offspring of 
pair- fed pregnancies showed similar constrictor sensitivity 
to PE (PD2, PF: 5.25 ± 0.08 vs. N: 5.31 ± 0.07; p > 0.05) and 
U46619 (PD2, PF: 7.25 ± 0.12 vs. N: 7.29 ± 0.11; p > 0.05) 
compared to adult offspring of normoxic pregnancy.
Maternal treatment with melatonin in hypoxic preg-
nancy normalized the constrictor sensitivity to PE and 
U46619 in mesenteric vessels from adult offspring 
(Figure 6A,B). In contrast, relative to adult offspring from 
normoxic pregnancy, maternal treatment with melatonin 
in normoxic pregnancy (Figure  6A,B) or pair- fed preg-
nancy (PD2, N: 5.31 ± 0.07 vs. PF: 5.00 ± 0.08; p > 0.05) 
and U46619 (PD2, N: 7.29 ± 0.11 vs. 7.19 ± 0.21; p >0 .05) 
had no effect on vascular sensitivity is mesenteric vessels 
isolated from adult offspring.
4 |  DISCUSSION
The data show that late- onset hypoxia in the last quarter of 
pregnancy in rats promotes significant fetal growth restric-
tion with evidence of fetal brain sparing, thickening of the 
aortic walls and a fall in cardiac eNOS protein expression 
in fetal life, accelerated postnatal catch- up growth and di-
lated cardiomyopathy with constrictor hyper- reactivity to 
neurogenic and local agonists in the peripheral vascula-
ture at adulthood. These adverse effects of hypoxic preg-
nancy on cardiovascular outcomes in the fetus and adult 
offspring are independent of hypoxia- induced reductions 
in maternal food intake. Conversely, the effects of hypoxic 
pregnancy on fetal and postnatal growth are similar than 
those induced by comparable reductions in maternal food 
intake in normoxic pregnancy. Maternal treatment with 
melatonin, in doses lower than those recommended to 
avoid jet lag, protected against the adverse effects of hy-
poxic pregnancy on the cardiovascular system of the fetal 
and adult offspring, but it did not affect alterations in fetal 
or postnatal growth. An increase in cardiac eNOS expres-
sion links a molecular mechanism to the protective effects 
of maternal melatonin in hypoxic pregnancy. Therefore, 
the data support the hypothesis tested that maternal treat-
ment with low doses of melatonin will protect the progeny 
against cardiovascular remodelling and dysfunction pro-
grammed by developmental hypoxia.
Chronic hypoxia is a major stimulus for HIF- 2α syn-
thesis, regulating the expression of several target genes in-
cluding erythropoietin or EPO, which enhances red blood 
cell production, and this effect is measured by an increase 
F I G U R E  4  Fetal and adult offspring cardiovascular remodelling. Values are the mean ± SEM for the aorta wall to lumen area ratio 
and the aorta wall and lumen areas expressed as a percentage of total vessel area in fetal offspring (A, B), and the left ventricular (LV) wall 
to lumen area ratio and the LV wall and lumen areas expressed as a percentage of total LV area in adult offspring (C, D) from normoxic (N; 
white bars), hypoxic (H; black bars), hypoxic + melatonin (HM; red bars) and normoxic + melatonin (NM; blue bars) pregnancies. There 
was a significant interaction between hypoxia and melatonin main effects for A- D. Post- hoc significant (p < 0.05) differences: *H vs. all 
(Two- way ANOVA + Tukey test)
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in packed red cell volume.53 We show that exposure of 
pregnant dams to 10% O2 for 5 days in late gestation led 
to significant increases in maternal and fetal haematocrit 
levels, suggesting HIF- 2α activation. Maternal treatment 
with melatonin did not affect the magnitude of the mater-
nal or fetal erythropoietic response, suggesting that mela-
tonin does not interfere with HIF- 2α activation in either 
mother or fetus, and therefore, both treated and untreated 
pregnancies were exposed to the same degree of hypoxia.
Our data show that basal plasma concentrations of 





















































































































































































































































































































































































































































































































































































































































































































F I G U R E  5  Cardiac protein expression of eNOS. Values are 
mean ± SEM for the protein expression relative to control for eNOS 
in hearts of fetal (A) and adult (B) offspring from normoxic (N; 
white bars), hypoxic (H; black bars), hypoxic + melatonin (HM; 
red bars) and normoxic + melatonin (NM; blue bars) pregnancies. 
There was a significant interaction between hypoxia and melatonin 
main effects for A and B. Post- hoc significant (p < 0.05) differences: 
*H vs. N; †HM vs. all; (Two- way ANOVA + Tukey test). 
Representative Coomassie blue, anti- eNOS and anti- βactin staining 
images are included in Figure S1
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with the fetus, and that maternal treatment with mela-
tonin resulted in greater levels of circulating melatonin 
in the mother than in the fetus. Combined, these data 
confirm that melatonin crosses the placenta, and that 
basal circulating melatonin in the fetus is of maternal or-
igin.26,54,55 The dose of melatonin treatment used in this 
study was based on previous studies showing protective 
actions of melatonin on fetal development,27 and it was 
less than the maximal dose recommended for overcoming 
jet lag in humans.42 The resulting concentration of mela-
tonin in maternal plasma following melatonin treatment 
was similar than that found in other studies using preg-
nant rats,56,57 and within the range or lower than those 
measured in men and women following melatonin intake 
to avoid jet lag.58
The cardiovascular data in the present study show that 
hypoxic pregnancy induced aortic wall thickening with-
out affecting the cardiac walls in fetal life. Conversely, 
adult offspring of hypoxic pregnancy showed cardiac wall 
thinning without an effect on the aortic walls. Maternal 
treatment with melatonin in hypoxic pregnancy nor-
malised the cardiovascular remodelling in both fetal and 
adult life. Aortic wall thickening during development 
complicated by chronic hypoxia has been reported in ro-
dent models of early- onset hypoxic pregnancy,4,6,9 ovine 
hypoxic pregnancy59 and in chicken embryos incubated 
under isobaric60 and hypobaric61 chronic hypoxia con-
ditions. Hypoxia- induced fetal aortic wall thickening is 
particularly relevant in the clinical setting, as it has also 
been reported in human infants and older children born 
from pregnancies complicated by fetal growth restric-
tion,62- 64 and both fetal aortic wall thickening as well as 
fetal growth restriction have been associated with an in-
creased risk of hypertension, atherosclerosis, peripheral 
vascular dysfunction, and coronary heart disease in later 
life.65- 67 The mechanisms underlying aortic wall remodel-
ling in hypoxic fetus are poorly understood but include an 
increase in vessel tension and pressure- induced load.68- 70 
F I G U R E  6  Peripheral vascular 
reactivity. Values are mean ± SEM 
for the concentration- response curves 
expressed as percentage of the maximal 
constriction induced by 125 mM 
potassium, the vascular sensitivity (pD2) 
and maximal contraction (%Kmax) 
in response to phenylephrine (PE, A) 
and the thromboxane mimetic U46619 
(B) in mesenteric arteries. Groups are 
normoxic (N; white symbols and bars), 
hypoxic (H; black symbols and bars), 
hypoxic + melatonin (HM; red symbols 
and bars) and normoxic + melatonin 
(NM; blue symbols and bars) pregnancies. 
For the line graphs, a log agonist versus 
response variable slope plot was used. 
Significant differences (p <0 .05): * vs. 
N, † vs H (Two- way ANOVA + Tukey 
test)
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It has also been reported that sustained load can over-
whelm cardiac wall remodelling, switching compensatory 
hypertrophic growth to dilated cardiomyopathy, which is 
preeminent of heart failure.71 Therefore, maternal treat-
ment with melatonin by normalising aortic wall tension 
and thickness may also protect against a dilated cardiomy-
opathy phenotype in later life.
To explore mechanisms of protection against cardiovas-
cular remodelling in fetal and adult life in hypoxic preg-
nancy treated with melatonin, we investigated changes in 
the cardiac expression of proteins associated with oxida-
tive stress and NO signalling, as well as programmed alter-
ations in peripheral vascular reactivity. Data in the present 
study show that the cardiac protein expression of eNOS 
was significantly reduced in the fetus but enhanced in the 
adult offspring of hypoxic pregnancy, without affecting the 
cardiac protein expression of HSP27, HSP70 or 4- HNE in 
the fetal or adult periods. Maternal treatment with mela-
tonin not only reversed but enhanced cardiac eNOS pro-
tein expression in the hypoxic fetus, normalising its levels 
of protein expression by adulthood. The cardioprotective 
effects of NO are well established.72 Indeed, NO produc-
tion by eNOS is of central importance in cardiac protection 
against ischaemic injury. Cardiac protection is enhanced 
in animals overexpressing eNOS73 and reduced in animals 
deficient of eNOS.74 These findings are consistent with im-
paired cardiac eNOS protein expression in fetal offspring, 
and a possible compensatory response in adult offspring of 
hypoxic pregnancy. It is also in keeping with the effects of 
melatonin enhancing cardiac eNOS protein expression in 
the fetus, negating the need for a compensatory response in 
the adult offspring of treated hypoxic pregnancy.
It is well established that hypoxic pregnancy pro-
grammes a vasoconstrictor phenotype in the periph-
eral vasculature of the adult offspring. For instance, 
sympathetic control of cardiovascular function is well 
developed by late incubation in the chicken embryo.75 
Further, chronic hypoxia stimulates periarterial sym-
pathetic nerve development in the chicken embryo.76 
In rats, hypoxic pregnancy leads to enhanced femoral 
vasoconstrictor responses in newborn pups77 as well 
as increased muscle sympathetic nerve activity, sym-
pathetic hyperinnervation, and hypertension in adult 
progeny.78 In sheep, chronic hypoxia during pregnancy 
enhances femoral vasoconstrictor responses to PE in 
the fetus,79 the intrauterine growth restriction fetus ex-
hibits a greater reliance on α- adrenergic activation for 
blood pressure regulation,80 and hypoxic pregnancy 
programmes femoral vasoconstrictor hyper- reactivity to 
various agonists in the adult offspring.10 Interestingly, 
the fetal llama, a species adapted to the chronic hypoxia 
of life at high altitude also shows a greater reliance on α- 
adrenergic mechanisms for the maintenance of arterial 
blood pressure regulation under basal and stimulated 
conditions.81 Consistent with these findings, data in the 
present study show that late- onset hypoxic pregnancy in 
rats also programmes constrictor hyper- reactivity to neu-
rogenic and paracrine agonists in the mesenteric circula-
tion of adult offspring. Further, maternal treatment with 
melatonin in hypoxic pregnancy prevents this program-
ming effect. The protective actions of melatonin against 
programmed peripheral vascular dysfunction may be 
due to its known effects as an anti- adrenergic agent,82 
as well as its inhibitory effects on thromboxane signal-
ling.83,84 Alternatively, we have reported that melatonin 
treatment in the fetus can increase NO bioavailability 
in the peripheral circulation, offsetting vasoconstrictor 
influences.85 Persistence of this effect into adulthood 
could provide another pathway explaining the benefi-
cial actions of melatonin on programmed constrictor 
hyper- reactivity. Accordingly, Tain et al.86 have reported 
that maternal treatment with melatonin can programme 
increased NO bioavailability in the adult offspring in 
several animal models of developmental programming. 
In turn, effects of melatonin offsetting a peripheral vaso-
constrictor phenotype via any of the mechanisms above 
will protect against cardiovascular remodelling in fetal 
and adult offspring of hypoxic pregnancy.
In contrast with the beneficial effects on cardiovascu-
lar structure and function in offspring of hypoxic preg-
nancy, maternal treatment with melatonin in the present 
study did not have an effect on fetal growth restriction or 
postnatal catch- up growth. Broadly, these findings do not 
support beneficial effects of melatonin on the offspring of 
hypoxic pregnancy to be simply due to protective effects at 
the level of placental perfusion. It is interesting that ma-
ternal treatment with melatonin restored fetal growth and 
birth weight in pair- fed normoxic pregnancies, but not in 
hypoxic pregnancies. The mechanisms mediating the pro-
tective effects of melatonin in undernourished pregnancy 
include an increase in placental antioxidant enzyme ex-
pression.27 Therefore, whilst melatonin treatment may 
protect placental perfusion in undernourished pregnancy 
by increasing antioxidant defences,27 this mechanism of 
protection against fetal growth restriction is not sufficient 
in hypoxic pregnancy. Combined, past and present data 
highlight that the effects on fetal and postnatal growth of 
hypoxic compared with undernourished pregnancy may 
be mediated via differential pathways.
In conclusion, we show that maternal treatment with 
melatonin in low doses confers significant protection 
against programmed adverse effects on cardiovascular 
structure and function in offspring of hypoxic pregnancy. 
Mechanisms underlying this protection by melatonin in-
clude stimulatory effects on cardiac eNOS protein expres-
sion and offsetting programmed constrictor hyper- reactivity 
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in the offspring of hypoxic pregnancy. The data support that 
maternal treatment with melatonin is a plausible therapy 
with good human translational potential to protect offspring 
against cardiovascular disease programmed by chronic fetal 
hypoxia during complicated pregnancy.
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